{
  "run": {
    "id": "cmnr15hwz06wmp658l8jhi8ra",
    "region": "US",
    "assetId": "cmnr15hwj06wip658enz23zm3",
    "ticker": "VRTX",
    "snapshotId": "cmnr15hwp06wkp658xc54d3s3",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:22:06.705Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr15hwp06wkp658xc54d3s3",
      "assetId": "cmnr15hwj06wip658enz23zm3",
      "asOf": "2026-04-08T20:00:00.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:00.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:00.000Z",
          "open": 436.25,
          "price": 443.92,
          "dayLow": 432.33,
          "volume": 1279267,
          "dayHigh": 443.99,
          "currency": "USD",
          "prevClose": 431.86,
          "week52Low": 362.5,
          "week52High": 510.77
        },
        "fundamentals": {
          "pe": 20.1104368932039,
          "beta": 1.46078166256664,
          "epsTTM": 8.24,
          "fcfTTM": 1175298000,
          "growth": {
            "epsYoy": 8.432692307692307,
            "revenueYoy": 0.0890373045616646
          },
          "sector": "Pharmaceutical Preparations",
          "margins": {
            "net": 0.3293976485880696,
            "gross": null,
            "operating": 0.3477373284560839
          },
          "website": null,
          "industry": null,
          "pegRatio": 0.0296895029342564,
          "ebitdaTTM": 2181718000,
          "forwardPe": 51.3034055727554,
          "marketCap": 113400000000,
          "totalCash": 1665412000,
          "totalDebt": 20496000,
          "debtEquity": 0.00443226612175362,
          "quickRatio": 2.93586824567054,
          "revenueTTM": 12001300000,
          "companyName": "VERTEX PHARMACEUTICALS INC / MA",
          "priceToBook": 9.50096924988552,
          "currentRatio": 3.281424819760672,
          "dividendYield": null,
          "returnOnAssets": 1.114829213872252,
          "returnOnEquity": 0.472784672990165,
          "analystOpinions": null,
          "businessSummary": null,
          "enterpriseValue": 39508251320,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": null,
          "sharesOutstanding": 254034190,
          "enterpriseToEbitda": 18.10878001648242,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 3.291997643588611,
          "operatingCashflowTTM": 3631400000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:22:06.697Z"
    },
    "results": [
      {
        "id": "cmnr15hx106wop6580t4wsrdg",
        "runId": "cmnr15hwz06wmp658l8jhi8ra",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"VRTX\",\"currency\":\"USD\",\"current_price\":443.92,\"target_price_6m\":462,\"target_price_12m\":480,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"CF franchise provides durable ~$10B+ revenue base with high margins\",\"Journavx launch in acute pain adds meaningful new growth vector\",\"Near-zero debt and strong cash generation fund pipeline reinvestment\",\"Trailing P/E of ~20x is reasonable for biotech compounder profile\",\"Pipeline diversification into pain, kidney, gene editing reduces CF concentration risk\"],\"key_drivers\":[{\"driver\":\"Trikafta/Kaftrio CF franchise durability and pricing power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Journavx (suzetrigine) commercial ramp in acute pain\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pipeline readouts in pain, kidney disease, gene editing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating leverage expanding EBIT margins over time\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Forward P/E at 51x signals market expects near-term earnings pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Beta of 1.46 implies elevated sensitivity to market selloffs\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Potential generic/biosimilar CF competition long-term\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Casgevy gene therapy adoption pace in sickle cell disease\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Forward P/E divergence from trailing P/E suggests possible earnings normalization or one-time TTM boost\",\"CF patent cliffs could threaten core revenue in outer years\",\"Journavx commercial uptake may underwhelm vs blockbuster expectations\",\"Regulatory or clinical trial setbacks in key pipeline programs\",\"Macro/tariff headwinds could compress biotech multiples given high beta\"],\"assumptions\":{\"revenue_cagr_3y\":0.12,\"ebit_margin_target\":0.38,\"wacc\":0.095,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":380,\"prob\":0.15,\"notes\":\"CF competition accelerates, Journavx disappoints, multiple compresses to ~16x earnings.\"},\"base\":{\"target_price\":480,\"prob\":0.60,\"notes\":\"Steady CF growth plus Journavx ramp; P/E sustains at ~20-22x on normalized earnings.\"},\"bull\":{\"target_price\":560,\"prob\":0.25,\"notes\":\"Journavx becomes multi-billion blockbuster, pipeline wins expand TAM, multiple re-rates to ~25x.\"}},\"method_notes\":\"Earnings-power valuation anchored on ~20x normalized EPS with 12% revenue CAGR. EV in snapshot ($39.5B) appears anomalous vs market cap ($113.4B); ignored in favor of P/E-based framework. Forward P/E (51.3x) vs trailing (20.1x) discrepancy flagged—may reflect one-time TTM gains or data lag. Sell-side targets not used as numeric inputs. Recommendation: ~8% 12M upside supports BUY at moderate confidence given pipeline uncertainty. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Forward P/E divergence from trailing P/E suggests possible earnings normalization or one-time TTM boost",
            "CF patent cliffs could threaten core revenue in outer years",
            "Journavx commercial uptake may underwhelm vs blockbuster expectations",
            "Regulatory or clinical trial setbacks in key pipeline programs",
            "Macro/tariff headwinds could compress biotech multiples given high beta"
          ],
          "ticker": "VRTX",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady CF growth plus Journavx ramp; P/E sustains at ~20-22x on normalized earnings.",
              "target_price": 480
            },
            "bear": {
              "prob": 0.15,
              "notes": "CF competition accelerates, Journavx disappoints, multiple compresses to ~16x earnings.",
              "target_price": 380
            },
            "bull": {
              "prob": 0.25,
              "notes": "Journavx becomes multi-billion blockbuster, pipeline wins expand TAM, multiple re-rates to ~25x.",
              "target_price": 560
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.12,
            "terminal_multiple": 22,
            "ebit_margin_target": 0.38
          },
          "key_drivers": [
            {
              "driver": "Trikafta/Kaftrio CF franchise durability and pricing power",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Journavx (suzetrigine) commercial ramp in acute pain",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pipeline readouts in pain, kidney disease, gene editing",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Operating leverage expanding EBIT margins over time",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Forward P/E at 51x signals market expects near-term earnings pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Beta of 1.46 implies elevated sensitivity to market selloffs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Potential generic/biosimilar CF competition long-term",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Casgevy gene therapy adoption pace in sickle cell disease",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Earnings-power valuation anchored on ~20x normalized EPS with 12% revenue CAGR. EV in snapshot ($39.5B) appears anomalous vs market cap ($113.4B); ignored in favor of P/E-based framework. Forward P/E (51.3x) vs trailing (20.1x) discrepancy flagged—may reflect one-time TTM gains or data lag. Sell-side targets not used as numeric inputs. Recommendation: ~8% 12M upside supports BUY at moderate confidence given pipeline uncertainty. Not investment advice.",
          "current_price": 443.92,
          "recommendation": "BUY",
          "thesis_bullets": [
            "CF franchise provides durable ~$10B+ revenue base with high margins",
            "Journavx launch in acute pain adds meaningful new growth vector",
            "Near-zero debt and strong cash generation fund pipeline reinvestment",
            "Trailing P/E of ~20x is reasonable for biotech compounder profile",
            "Pipeline diversification into pain, kidney, gene editing reduces CF concentration risk"
          ],
          "target_price_6m": 462,
          "target_price_12m": 480
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 48173,
        "createdAt": "2026-04-09T05:22:06.705Z",
        "usage": {
          "inputTokens": 3497,
          "outputTokens": 2220,
          "costUsd": 0.072985
        }
      },
      {
        "id": "cmnr15hx106wrp6584ogr0fkn",
        "runId": "cmnr15hwz06wmp658l8jhi8ra",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:00.000Z\",\n  \"ticker\": \"VRTX\",\n  \"currency\": \"USD\",\n  \"current_price\": 443.92,\n  \"target_price_6m\": 450,\n  \"target_price_12m\": 460,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\n    \"CF franchise drives stable revenue growth.\",\n    \"Pipeline has potential in new indications.\",\n    \"High margins and strong cash position.\",\n    \"Valuation rich relative to near-term growth.\",\n    \"Balanced risk-reward at current levels.\"\n  ],\n  \"key_drivers\": [\n    {\"driver\": \"CF drug sales\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Pipeline progress\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Competition intensity\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Regulatory environment\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Pricing pressures\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"R&D productivity\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Macro conditions\", \"impact\": \"LOW\", \"direction\": \"NEG\"}\n  ],\n  \"risks\": [\"Clinical trial setbacks\", \"Patent cliffs\", \"Regulatory changes\", \"Market volatility\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.09,\n    \"ebit_margin_target\": 0.35,\n    \"wacc\": 0.08,\n    \"terminal_multiple\": 18\n  },\n  \"scenarios\": {\n    \"bear\": {\"target_price\": 400, \"prob\": 0.2, \"notes\": \"Earnings miss leads to P/E decline.\"},\n    \"base\": {\"target_price\": 460, \"prob\": 0.6, \"notes\": \"Moderate growth with stable multiples.\"},\n    \"bull\": {\"target_price\": 520, \"prob\": 0.2, \"notes\": \"Pipeline successes drive upside.\"}\n  },\n  \"method_notes\": \"Valuation based on DCF with growth and margin assumptions. HOLD as expected return is minimal. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Clinical trial setbacks",
            "Patent cliffs",
            "Regulatory changes",
            "Market volatility"
          ],
          "ticker": "VRTX",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Moderate growth with stable multiples.",
              "target_price": 460
            },
            "bear": {
              "prob": 0.2,
              "notes": "Earnings miss leads to P/E decline.",
              "target_price": 400
            },
            "bull": {
              "prob": 0.2,
              "notes": "Pipeline successes drive upside.",
              "target_price": 520
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.08,
            "revenue_cagr_3y": 0.09,
            "terminal_multiple": 18,
            "ebit_margin_target": 0.35
          },
          "key_drivers": [
            {
              "driver": "CF drug sales",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pipeline progress",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Competition intensity",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory environment",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pricing pressures",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "R&D productivity",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Macro conditions",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on DCF with growth and margin assumptions. HOLD as expected return is minimal. Not investment advice.",
          "current_price": 443.92,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "CF franchise drives stable revenue growth.",
            "Pipeline has potential in new indications.",
            "High margins and strong cash position.",
            "Valuation rich relative to near-term growth.",
            "Balanced risk-reward at current levels."
          ],
          "target_price_6m": 450,
          "target_price_12m": 460
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 352,
        "createdAt": "2026-04-09T05:22:06.705Z",
        "usage": {
          "inputTokens": 2021,
          "outputTokens": 4276,
          "costUsd": 0.002362
        }
      },
      {
        "id": "cmnr15hx106wpp658p9i8os29",
        "runId": "cmnr15hwz06wmp658l8jhi8ra",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Vertex Pipeline & DCF Model\",\n  \"as_of\": \"2026-04-08T20:00:00.000Z\",\n  \"ticker\": \"VRTX\",\n  \"currency\": \"USD\",\n  \"current_price\": 443.92,\n  \"target_price_6m\": 465.00,\n  \"target_price_12m\": 485.00,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"Unrivaled monopoly in Cystic Fibrosis provides highly durable, high-margin cash flows.\",\n    \"Casgevy launch adds a new revenue pillar but faces complex commercialization hurdles.\",\n    \"Suzetrigine offers massive blockbuster potential in the acute non-opioid pain market.\",\n    \"Pristine balance sheet with virtually no debt allows for aggressive pipeline M&A.\",\n    \"Valuation is demanding, requiring flawless pipeline execution to drive further multiple expansion.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"CF Franchise Durability\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Suzetrigine (VX-548) Launch\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Casgevy Commercialization\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"R&D Milestone Expenses\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Inaxaplin Phase 3 Data\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Pricing & Reimbursement Pressure\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Slower-than-expected adoption of Casgevy due to treatment center bottlenecks.\",\n    \"Clinical trial failures in early-stage pipeline assets like T1D and APOL1.\",\n    \"Over-reliance on the Cystic Fibrosis franchise for near-term cash flow.\",\n    \"Regulatory pushback or pricing pressure on new blockbuster launches.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.085,\n    \"ebit_margin_target\": 0.35,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 18.0\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 380.00,\n      \"prob\": 0.25,\n      \"notes\": \"Pipeline setbacks and slower Casgevy uptake compress the premium valuation multiple.\"\n    },\n    \"base\": {\n      \"target_price\": 485.00,\n      \"prob\": 0.55,\n      \"notes\": \"Steady CF cash flows and moderate pipeline success justify a 9% upside.\"\n    },\n    \"bull\": {\n      \"target_price\": 550.00,\n      \"prob\": 0.20,\n      \"notes\": \"Rapid Suzetrigine adoption and flawless Casgevy execution drive significant earnings beats.\"\n    }\n  },\n  \"method_notes\": \"Valuation based on a 10-year DCF and SOTP analysis, anchoring on durable CF cash flows and risk-adjusted pipeline revenues. High forward P/E reflects heavy R&D investments. Upside is moderate, supporting a BUY rating. This is not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "Vertex Pipeline & DCF Model",
          "risks": [
            "Slower-than-expected adoption of Casgevy due to treatment center bottlenecks.",
            "Clinical trial failures in early-stage pipeline assets like T1D and APOL1.",
            "Over-reliance on the Cystic Fibrosis franchise for near-term cash flow.",
            "Regulatory pushback or pricing pressure on new blockbuster launches."
          ],
          "ticker": "VRTX",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Steady CF cash flows and moderate pipeline success justify a 9% upside.",
              "target_price": 485
            },
            "bear": {
              "prob": 0.25,
              "notes": "Pipeline setbacks and slower Casgevy uptake compress the premium valuation multiple.",
              "target_price": 380
            },
            "bull": {
              "prob": 0.2,
              "notes": "Rapid Suzetrigine adoption and flawless Casgevy execution drive significant earnings beats.",
              "target_price": 550
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.085,
            "terminal_multiple": 18,
            "ebit_margin_target": 0.35
          },
          "key_drivers": [
            {
              "driver": "CF Franchise Durability",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Suzetrigine (VX-548) Launch",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Casgevy Commercialization",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "R&D Milestone Expenses",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Inaxaplin Phase 3 Data",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pricing & Reimbursement Pressure",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on a 10-year DCF and SOTP analysis, anchoring on durable CF cash flows and risk-adjusted pipeline revenues. High forward P/E reflects heavy R&D investments. Upside is moderate, supporting a BUY rating. This is not investment advice.",
          "current_price": 443.92,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Unrivaled monopoly in Cystic Fibrosis provides highly durable, high-margin cash flows.",
            "Casgevy launch adds a new revenue pillar but faces complex commercialization hurdles.",
            "Suzetrigine offers massive blockbuster potential in the acute non-opioid pain market.",
            "Pristine balance sheet with virtually no debt allows for aggressive pipeline M&A.",
            "Valuation is demanding, requiring flawless pipeline execution to drive further multiple expansion."
          ],
          "target_price_6m": 465,
          "target_price_12m": 485
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-pro-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 28356,
        "createdAt": "2026-04-09T05:22:06.705Z",
        "usage": {
          "inputTokens": 2357,
          "outputTokens": 873,
          "costUsd": 0.01519
        }
      },
      {
        "id": "cmnr15hx106wnp6588z8pjhos",
        "runId": "cmnr15hwz06wmp658l8jhi8ra",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"VRTX\",\"currency\":\"USD\",\"current_price\":443.92,\"target_price_6m\":456,\"target_price_12m\":468,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"CF franchise delivers durable cash flow and pricing power.\",\"Journavx and Casgevy add diversification, but near-term scale remains uncertain.\",\"Margins and balance sheet support deep R&D and business development.\",\"Valuation already reflects meaningful pipeline success after the recent recovery.\",\"Balanced upside and downside support only modest 12-month appreciation.\"],\"key_drivers\":[{\"driver\":\"CF franchise durability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Journavx launch uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Casgevy reimbursement and capacity\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline readouts beyond CF\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"R&D investment drag\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"CF revenue concentration\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Drug pricing and payer pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Net cash balance sheet\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"CF franchise concentration\",\"Pipeline setbacks or slower launches\",\"Gene-editing reimbursement or manufacturing delays\",\"US pricing or payer pressure\",\"Future competitive or patent erosion\"],\"assumptions\":{\"revenue_cagr_3y\":0.1,\"ebit_margin_target\":0.38,\"wacc\":0.09,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":370,\"prob\":0.25,\"notes\":\"CF growth slows and new launches disappoint.\"},\"base\":{\"target_price\":468,\"prob\":0.5,\"notes\":\"Core CF stays resilient; new products contribute gradually.\"},\"bull\":{\"target_price\":560,\"prob\":0.25,\"notes\":\"Journavx scales well and pipeline de-risks materially.\"}},\"method_notes\":\"Base case uses a blend of normalized EBIT/FCF thinking and scenario weighting anchored to snapshot price, revenue, margins, and balance sheet. 12M upside is about 5%, below BUY threshold, so HOLD. Snapshot EV-related fields appear internally inconsistent, so weight was placed on other snapshot fundamentals. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "OpenAI o3",
          "risks": [
            "CF franchise concentration",
            "Pipeline setbacks or slower launches",
            "Gene-editing reimbursement or manufacturing delays",
            "US pricing or payer pressure",
            "Future competitive or patent erosion"
          ],
          "ticker": "VRTX",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Core CF stays resilient; new products contribute gradually.",
              "target_price": 468
            },
            "bear": {
              "prob": 0.25,
              "notes": "CF growth slows and new launches disappoint.",
              "target_price": 370
            },
            "bull": {
              "prob": 0.25,
              "notes": "Journavx scales well and pipeline de-risks materially.",
              "target_price": 560
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.1,
            "terminal_multiple": 22,
            "ebit_margin_target": 0.38
          },
          "key_drivers": [
            {
              "driver": "CF franchise durability",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Journavx launch uptake",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Casgevy reimbursement and capacity",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pipeline readouts beyond CF",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "R&D investment drag",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "CF revenue concentration",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Drug pricing and payer pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Net cash balance sheet",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Base case uses a blend of normalized EBIT/FCF thinking and scenario weighting anchored to snapshot price, revenue, margins, and balance sheet. 12M upside is about 5%, below BUY threshold, so HOLD. Snapshot EV-related fields appear internally inconsistent, so weight was placed on other snapshot fundamentals. not investment advice",
          "current_price": 443.92,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "CF franchise delivers durable cash flow and pricing power.",
            "Journavx and Casgevy add diversification, but near-term scale remains uncertain.",
            "Margins and balance sheet support deep R&D and business development.",
            "Valuation already reflects meaningful pipeline success after the recent recovery.",
            "Balanced upside and downside support only modest 12-month appreciation."
          ],
          "target_price_6m": 456,
          "target_price_12m": 468
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0c7fced8e81521690069d75e8eb49c8190b0038afb4d3afa9b",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 46214,
        "createdAt": "2026-04-09T05:22:06.705Z",
        "usage": {
          "inputTokens": 2292,
          "outputTokens": 2656,
          "costUsd": 0.041195
        }
      },
      {
        "id": "cmnr15hx106wqp658uumuhus4",
        "runId": "cmnr15hwz06wmp658l8jhi8ra",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:00.000Z\",\n  \"ticker\": \"VRTX\",\n  \"currency\": \"USD\",\n  \"current_price\": 443.92,\n  \"target_price_6m\": 455,\n  \"target_price_12m\": 465,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\n    \"Dominant CF market position drives stable revenues\",\n    \"Promising pipeline in pain and kidney therapies\",\n    \"High forward PE ratio of 51x suggests rich valuation\",\n    \"Strong cash flow and near-zero debt balance sheet\",\n    \"Biotech volatility from clinical and regulatory risks\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Cystic fibrosis drug sales\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Pipeline advancement in non-CF\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Operating margin expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Patent protection duration\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competition in CF treatments\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Regulatory approval timelines\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"R&D investment returns\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Broader biotech sector sentiment\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Clinical trial failures\",\n    \"Loss of patent exclusivity\",\n    \"Reimbursement challenges\",\n    \"Pipeline diversification delays\",\n    \"Valuation contraction\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.08,\n    \"ebit_margin_target\": 0.35,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 25\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 350,\n      \"prob\": 0.25,\n      \"notes\": \"Multiple pipeline failures cause sharp de-rating.\"\n    },\n    \"base\": {\n      \"target_price\": 465,\n      \"prob\": 0.55,\n      \"notes\": \"Modest growth and mixed pipeline results.\"\n    },\n    \"bull\": {\n      \"target_price\": 590,\n      \"prob\": 0.2,\n      \"notes\": \"Blockbuster approvals in pain and renal drive upside.\"\n    }\n  },\n  \"method_notes\": \"DCF using 8% rev CAGR, 35% EBIT margin, 8.5% WACC, 25x terminal. Balanced risks and rich valuation support HOLD. not investment advice\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Clinical trial failures",
            "Loss of patent exclusivity",
            "Reimbursement challenges",
            "Pipeline diversification delays",
            "Valuation contraction"
          ],
          "ticker": "VRTX",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Modest growth and mixed pipeline results.",
              "target_price": 465
            },
            "bear": {
              "prob": 0.25,
              "notes": "Multiple pipeline failures cause sharp de-rating.",
              "target_price": 350
            },
            "bull": {
              "prob": 0.2,
              "notes": "Blockbuster approvals in pain and renal drive upside.",
              "target_price": 590
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.08,
            "terminal_multiple": 25,
            "ebit_margin_target": 0.35
          },
          "key_drivers": [
            {
              "driver": "Cystic fibrosis drug sales",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pipeline advancement in non-CF",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Operating margin expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Patent protection duration",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competition in CF treatments",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory approval timelines",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "R&D investment returns",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Broader biotech sector sentiment",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using 8% rev CAGR, 35% EBIT margin, 8.5% WACC, 25x terminal. Balanced risks and rich valuation support HOLD. not investment advice",
          "current_price": 443.92,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Dominant CF market position drives stable revenues",
            "Promising pipeline in pain and kidney therapies",
            "High forward PE ratio of 51x suggests rich valuation",
            "Strong cash flow and near-zero debt balance sheet",
            "Biotech volatility from clinical and regulatory risks"
          ],
          "target_price_6m": 455,
          "target_price_12m": 465
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "12ee077e-2c09-9560-86fe-a99d11e9acab",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 26086,
        "createdAt": "2026-04-09T05:22:06.705Z",
        "usage": {
          "inputTokens": 2632,
          "outputTokens": 4179,
          "costUsd": 0.070581
        }
      }
    ]
  }
}